Published On : 10 June 2025
• The Global Recombinant Human Erythropoietin for Injection market was valued at USD 9,168 million in 2023, and it is anticipated to reach approximately USD 15,754.16 million by 2032, growing at a CAGR of 6.20% over the forecast period. This robust growth is attributed to the increasing prevalence of anemia due to chronic diseases, rising demand for biosimilars, and expanding healthcare access in developing regions.
Email: help@intelmarketresearch.com
• The Recombinant Human Erythropoietin (rEPO) for Injection market is a vital part of the global biopharmaceutical market, driven by its necessary function in treating anemia linked to chronic kidney disease, cancer, and HIV/AIDS. rEPO is a man-made version of a naturally occurring hormone that promotes the production of red blood cells, commonly used to treat anemia due to low erythropoietin levels or dysfunctional bone marrow. The market has been experiencing consistent growth year after year driven by growing incidences of chronic conditions, rising geriatric populations, and wider access to dialysis and chemotherapy procedures. Advances in biologics production technology and wider availability of biosimilar erythropoietins are also driving the market expansion, particularly in the emerging nations. As healthcare systems place emphasis on low-cost and effective treatment for anemia, the rEPO market keeps developing with the help of robust demand in both developed and developing regions.Increasing cancer incidence is a key growth driver for the market. For example, based on the Centers for Disease Control and Prevention (CDC) 2020 data, 1,603,844 new cancer cases were reported with 602,347 people succumbing to this disease, in U.S
Email:
•Epoetin Alfa •Epoetin Beta •Darbepoetin Alfa •Biosimilars
Amgen
Johnson & Johnson
Roche
Kyowa Kirin
LG Chem
Daewoong Pharmaceutical •Wockhardt
